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To develop a nontoxic system for targeting therapy, a new highly ordered hierarchical mesoporous calcium
carbonate nanospheres (CCNSs) as small drug carriers has been synthesized by a mild and facile binary solvent
approach under the normal temperature and pressure. The hierarchical structure by multistage self-assembled
strategy was confirmed by TEM and SEM, and a possible formation process was proposed. Due to the large fraction
of voids inside the nanospheres which provides space for physical absorption, the CCNSs can stably encapsulate
the anticancer drug etoposide with the drug loading efficiency as high as 39.7 wt.%, and etoposide-loaded CCNS
(ECCNS) nanoparticles can dispersed well in the cell culture. Besides, the drug release behavior investigated at three
different pH values showed that the release of etoposide from CCNSs was pH-sensitive. MTT assay showed that
compared with free etoposide, ECCNSs exhibited a higher cell inhibition ratio against SGC-7901 cells and also
decreased the toxicity of etoposide to HEK 293 T cells. The CLSM image showed that ECCNSs exhibited a high
efficiency of intracellular delivery, especially in nuclear invasion. The apoptosis test revealed that etoposide
entrapped in CCNSs could enhance the delivery efficiencies of drug to achieve an improved inhibition effect on cell
growth. These results clearly implied that the CCNSs are a promising drug delivery system for etoposide in cancer
therapy.
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Because of drug resistance, low bioavailability, and un-
desired severe side effects, the therapeutic effect of
chemotherapy has been greatly limited for the treatment
of cancer [1-5]. The application of many antitumor
drugs, such as curcumin, PPT, and etoposide, has been
limited because of their disadvantages of poor water
solubility, metabolic inactivation, myelosuppression, side
effect for normal tissue, and poor targeting [6].
To overcome these limitations, drug delivery tech-
niques have been intensively investigated and studied to
improve the therapeutic effect [7]. Compared with con-
ventional formulations, an ideal anticancer drug delivery
system shows numerous advantages compared with
conventional formulation, such as improved efficacy, re-
duced toxicity, and reduced frequency of doses [8].* Correspondence: sundongmei@tongji.edu.cn; wsl@tongji.edu.cn
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in any medium, provided the original work is pBesides, the nanocarriers for anticancer drugs can also
take advantage of the enhanced permeation and reten-
tion (EPR) effect [9-11] in the vicinity of tumor tissues
to facilitate the internalization of drugs in tumors. Drug
carriers with diameters less than 600 nm may be taken
up selectively by tumor tissues because of the higher
permeation of tumor vasculature [12]. Multiplicity car-
rier and functional nanoparticles exhibit greatly en-
hanced therapeutic effects and can improve the
dispersion stability of the particles in water and endow
the particles with long circulation property in vivo
[8,12-18]. However, the nanoscale drug delivery systems
may also exhibit some disadvantages, such as poor bio-
compatibility, incompletely release in vivo, and incom-
plete degradation. Therefore, people are constantly
developing delivery systems which are easily prepared,
environment-friendly, and biocompatible.
CaCO3, the most common inorganic material of the
nature, widely exists in living creatures and even in someOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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calcium carbonate in recent years, but not so much
attention has been focused on its biological effects.
Compared with other inorganic materials, CaCO3 has
shown promising potential for the development of smart
carriers for anticancer drugs [19] because of its ideal bio-
compatibility, biodegradability, and pH-sensitive properties,
which enable CaCO3 to be used for controlled degradability
both in vitro and in vivo [20]. It has been used as a vector
to deliver genes, peptide, proteins, and drug [21-23].
Furthermore, spherical CaCO3 particle might be found in
its uses in catalysis, filler, separations technology, coatings,
pharmaceuticals and agrochemicals [24,25].
Etoposide, a derivative of the anticancer drug podo-
phyllotoxin, is an important chemotherapeutic agent for
the treatment of cell lung cancer [26], testicular carcinoma
[27], and lymphomas [28]. Its direct applications had been
limited by its poor water solubility, side effect for normal
tissue, and poor targeting. Therefore, an efficient drug
delivery system is desired to overcome these drawbacks
and improve its clinical therapy efficiency.
Considering that the dimensional and structural char-
acteristics of the materials endow them a wide range of
remarkable properties and potential applications, the
design and synthesis of materials with specific morph-
ologies have drawn significant attention [29-31]. Among
the different morphological nanostructures, the hier-
archical particles from nanometer to micrometer dimen-
sions reveal the great desirable properties. They have
been attracting considerable attention, owing to their
widespread applications in catalysis, chemical reactors,
drug delivery, controlled release of various substances,
protection of environmentally sensitive biological mole-
cules, and lightweight filler materials [19,32-37]. Highly
orderly hierarchical and pH value-sensitive calcium car-Figure 1 Schematic illustration for the synthesis of CCNSs.bonate can stably preserve drug under physiological con-
ditions and selectively release in the intracellular acid
environment [38]. Han et al. reported the mesoporous
hollow CaCO3 spheres prepared in guanidinium ionic li-
quid, but the surface area of those products is very low,
even only 17 m2/g [39]. It is still attractive to prepare
mesoporous high-surface area carbonates with unique
morphology and structure.
Herein, a crystallization of mesoporous calcium car-
bonate nanospheres (CCNSs) with hierarchical struc-
ture was prepared by a new facile binary solvent
method which is involved in the multistage self-
assembly of calcium carbonate crystallites into hier-
archical spheres under the templating effect of CO2 (as
shown in Figure 1). These prepared CCNSs have high
surface areas, even up to 82.14 m2/g, and show the ty-
pical mesoporous properties. The method is mild, eas-
ily performed, and environment-friendly, which is
based on a biomimetic system supported liquid mem-
brane used by Sun [40] and mixed-solvent method
used by Qian [41]. Etoposide-loaded strontium carbo-
nate nanoparticles have been studied by our group
[41]. However, there could be an existing problem
about the enrichment of strontium toxicity after stron-
tium carbonate degradation in vivo. Therefore, CCNSs
were used as the carrier for etoposide in this study; the
drug loading efficiency and the drug release behaviors
were also evaluated. Moreover, in vitro cellular ex-
periments with MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide) assay and fluorescence-
activated cell sorter (FACS) analysis were carried out
to evaluate the anticancer effect of etoposide-loaded
CCNSs. Meanwhile, confocal laser scanning micros-
copy (CLSM) image was utilized to investigate the up-
take of CCNSs by cancer cells. The possible mechanism
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Etoposide (≥98%) was a kind gift from the University of
Science and Technology of China. Dimethyl sulfoxide
(DMSO) and MTT formazan were purchased from
Sigma Chemical Co. (St Louis, MO, USA). CaCl2 (ana-
lytical reagent (AR)), Na2CO3 (AR), citric acid (AR), HCl
(36%–38%), and ethanol (AR) were purchased from
Sinopharm Chemical Regent Co., Ltd. (Shanghai, China)
and were used without further purification. Dulbecco's
modified Eagle medium (DMEM) (high glucose), RPMI-
1640, fetal calf serum (FCS), penicillin G, streptomycin,
and trypsinase were obtained from GIBCOBRL (Grand
Island, New York, NY, USA). Deionized water was
decarbonated by boiling before its use in all of the
applications.
Synthesis of etoposide-loaded calcium carbonate
nanospheres
All the experiments were prepared at room temperature.
Etoposide-loaded calcium carbonate nanospheres were
synthesized by mixing calcium chloride and sodium car-
bonate aqueous solution in the presence of ethanol, cit-
ric acid, and etoposide. Etoposide (0.2 g) and 10 mL
CaCl2 (0.1 M) were dissolved in 60 mL mixed solvent of
ethanol and deionized water (volume ratio = 1:2),
marked as solution A. Na2CO3 (0.02 g) and 10 mL of
Na2CO3 (0.1 M) were dissolved in 60 mL mixed solvent
of ethanol and deionized water (volume ratio = 1:2),
marked as solution B. Solution B was added dropwise
to the vigorously stirred solution A. With the reaction
proceeding, the milky white precipitation was obtained
after 72 h at room temperature. The precipitation was
washed thrice with mixed solvent of ethanol and de-
ionized water (volume ratio = 1:2) and dried using
vacuum freeze drier. The blank carrier CCNSs were
prepared without the addition of etoposide, and other
experimental parameters were similar to the ECCNSs
sample.
Characterization
The morphology of the ECCNSs was viewed by field-
emission scanning electron microscopy (Hitachi S4800,
Chiyoda-ku, Japan) at an acceleration voltage of 1 to 5 kV
and a JEOL 1230 transmission electron micrograph
(TEM, Akishima-shi, Japan) at an acceleration voltage of
200 kV. Brunauer-Emmett-Teller (BET) surface area and
pore distribution of the CaCO3 products were deter-
mined from N2 adsorption-desorption isotherms using a
Micromeritics TriStar 3000 system (Norcross, GA,USA). The zeta potential distribution of nanoparticles
was analyzed by Nano ZS, Malvern Instruments Ltd.,
Southborough, MA, USA. Fourier transform infrared
measurement was recorded on a Bruker Vector 22 spec-
trophotometer (Madison, WI, USA) in the range of
4,000 to 500 cm−1 using the standard KBr disk method
(sample/KBr = 1/100). UV–vis spectra were measured
on a CARY50 spectrophotometer (Varian, Victoria,
Australia). The crystallographic structure of the solid
samples was recorded using an X-ray diffraction (XRD,
Bruker D8) with Cu Kα radiation (λ = 0.154056 nm)
(Karlsruhe, Germany), using a voltage of 40 kV, a
current of 40 mA, and a scanning rate of 0.02°/s, in 2θ
ranges from 10° to 70°. The average particle size (z-aver-
age size) and size distribution were measured by photon
correlation spectroscopy (LS230 Beckman Coulter, Ful-
lerton, CA, USA) under a fixed angle of 90° in dispos-
able polystyrene cuvettes at 25°C.
Sedimentation study in RPMI-1640 medium
Etoposide (5 mg) was placed in a centrifugal tube of 15
mL and resuspended with 10 mL RPMI-1640 medium
supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin solution. The tube then stood
for over 4 h after vortexing for 2 min. Photographs of
the sample were taken at 1 h, 2 h, and 4 h. Other sam-
ples were studied in the same way. Based on the drug
encapsulation efficiency, the same quantity of etoposide
was applied to all formulations for the sedimentation
study.
Determination of loading amount and in vitro release test
The amount of incorporated etoposide was measured
through UV–vis spectroscopy. A known weight of
ECCNS sample was placed in a 10-mL flask, then 100
μL of 3 M HCl solution was subsequently added into it,
and the flask was filled with 100% phosphate buffer
solution (PBS) (pH = 7.4) until total volume reached 10
mL. After the ECCNS sample was totally dissolved, the
concentration of etoposide was determined with a
UV–vis spectrophotometer at 285 nm. The concentra-
tion of etoposide was calculated according to an already
obtained calibrating curve of etoposide (Abs = 0.00645c +
0.01599, r = 0.99923). The drug loading capacity and
encapsulation efficiency are calculated as follows:
drug loading capacity ¼ weight of etoposide in ECCNSs
weight of ECCNSs
 100%
The etoposide release test was performed in 180 mL
PBS at pH 7.4, 5.8, and 3.0. ECCNS (25 mg) was
resuspended in 10 mL PBS and loaded in a dialysis bag.
The release system was swayed in a bath reciprocal
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above for 120 h. Aliquots (2 mL) were extracted at desired
time intervals, and another 2 mL fresh PBS was added to
the system. The accumulated amount of etoposide re-
leased was determined by UV absorption at 285 nm.
Cytotoxicity assay
Cytotoxicity was characterized by MTT test through the
human embryonic kidney (HEK) 293 T cells. 293 T cells
with a density of 1 × 104 cells/well were seeded on a 96-
well polystyrene plate, and each well contained 100 μL
of DMEM (high glucose) medium supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin
solution. Cells were subsequently incubated at 37°C in a
5% CO2 humid incubator for 24 h. CCNSs, etoposide,
and ECCNSs were added to the wells with concentra-
tions 5, 10, 20, and 40 μg/mL in sequence. The HEK 293
T cells were incubated as described above for 24 and 48
h. A control experiment was performed with pure cul-
ture medium without treatment. Then, 20 μL (5 mg/mL)
of MTT was added to each well, and the plate was
further incubated for 4 h to deoxidize MTT under light-
blocking condition. After removal of the MTT dye
solution, cells were treated with 150 μL DMSO, and the
absorbance at 490 nm was measured using ELX 800 UV
reader (BioTek, Winooski, VT, USA), and cell viability
was calculated by:
Cell viability %ð Þ ¼ OD490 testð Þ−OD490 blankð Þ
OD490 controlð Þ−OD490 blankð Þ
 100%
Inhibition against SGC-7901 cells
The antitumor effect of CCNSs, etoposide, and ECCNSs
against human gastric carcinoma (SGC-7901) cells was
examined by cell viability test. SGC-7901 cells with a
density of 8 × 104 cells/well were seeded on a 96-well
polystyrene plate, and each well contained 100 μL of
RPMI-1640 medium supplemented with 10% fetal bo-
vine serum and 1% penicillin-streptomycin solution.
Cells were incubated at 37°C in a 5% CO2 humid incu-
bator for 24 h. Triplicate wells were treated with CCNSs,
free etoposide, and ECCNSs in different concentrations
of 5, 10, 20, and 40 μg/mL. These SGC-7901 cells were
incubated as described above for 24 and 48 h. MTT of
20 μL (5 mg/mL) was added to each well before the cells
were incubated for 4 h at 37°C under light-blocking con-
dition. After the removal of the MTT dye solution, cells
were treated with 150 μL DMSO. Absorbance was mea-
sured at 490 nm using ELX 800 reader, and inhibition
against SGC-7901 cells was calculated by the following
equation:Inhibition %ð Þ ¼ 1− OD490 testð Þ−OD490 blankð Þ
OD490 controlð Þ−OD490 blankð Þ
 
 100%
Fluorescence activated cell sorter analysis
The number of the apoptosis cells was determined with
the Annexin V-PI detection kit (KeyGEN Biotech). SGC-
7901 cells with 1 × 106 were cultured, suspended in
RPMI-1640 with 10% pasteurized FCS, and seeded on a
24-well flat-bottomed plate and incubated for 24 h at
37°C. The free etoposide, ECCNSs, and culture medium
were only added to each group with the concentration
of 30 μg/mL. Based on the drug encapsulation efficiency,
the same quantity of etoposide was applied to all formu-
lations for the apoptosis analysis. The incubation conti-
nued for 24 h at 37°C. Then, the cells were harvested
and washed with PBS, and then PI and Annexin V were
added directly to the cell suspended in the binding buf-
fer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH
7.4). The cells were incubated in the dark for 15 min at
37°C and submitted to FACS analysis on a Beckton-
Dickinson (Mountain View, CA, USA) spectrophotometer.
Confocal laser scanning microscopy
CLSM images of the ECCNSs and etoposide were obtained
using confocal laser scanning microscope (Leica, Wetzlar,
Germany) equipped with an oil immersion objective (60×,
Zeiss, Oberkochen, Germany). A suspension of the particles
was placed on a glass slide and dried prior to use. Fluores-
cence images were obtained at an excitation wavelength of
488 nm (fluorescein isothiocyanate (FITC)) and 405 nm
(4',6-diamidino-2-phenylindole (DAPI)).
Results and discussion
As shown in Figure 1, CCNSs were obtained by a multi-
stage self-assembled strategy. In this study, a series of in-
termediates were trapped, in order to confirm the
formation process of the CCNSs. It was found that the
nanoparticles firstly concentrated and arranged in a line
at an early stage. Then, the particles grew rapidly into
the broom shape via crystallization of nanoparticles
coupled with a simultaneous multiscale assembly. With
the reaction going on, the broom-like structure formed
into a high-order spherical structure, as shown in
Figure 2. The CCNSs were synthesized by a binary sol-
vent method. Firstly, the reaction of citric acid with
HCO3
− ions generates CO2 bubbles and H2O. And then,
the CO2 bubbles serve as not only the template of
engineered nanospheres but also the reactive materials
(reaction formulas listed below). Furthermore, citric acid
acts as a crystal modifier to control the selectivity of
polymorph and crystal morphology. Citric acid may be
coupled by hydrogen bond with etoposide, which can be
Figure 2 SEM images of ECCNSs.
Peng et al. Nanoscale Research Letters 2013, 8:321 Page 5 of 11
http://www.nanoscalereslett.com/content/8/1/321suggested from the structural formula. Then, the carbanion
of citric acid can bond with calcium ions. Accordingly, the
synthesis of ECCNSs based on high concentration of
hydrophobic drugs (etoposide) could be involved in the
crystallization of CCNSs in alcohol-water systems where
alcohol can be volatile slowly during the rapid stirring
synthetic system. As the ions in blood can destroy
hydrogen bonds, the drug will be released from the syn-
thetic calcium carbonate nanospheres.
2RCOOH aqð Þ þ CO2−3 ¼ 2RCOO− þH2O aqð Þ þ CO2 gð Þ
CO2 gð Þ⇌CO2 aqð Þ
CO2 aqð Þ þH2O aqð Þ⇌HCO−3 þHþ
HCO−3⇌H
þ þ CO2−3
Ca2þ þ CO2−3 ¼ CaCO3 sð Þ
The morphology of sphere-shaped nanoparticles was
confirmed by TEM and SEM (Additional file 1: Figure S1).Figure 3 Nitrogen adsorption-desorption isotherms of the obtained C
distribution curve determined from the N2 desorption isotherm.As shown in Figure 2, nanoparticles synthesized via binary
solvent method exhibited uniform size and good dispersal.
It can be observed that the ECCNSs are large spheres with
the diameter of about 2 μm. Meanwhile, some small
nanocrystals with the size of about 50 to 200 nm (secon-
dary nanoparticles) can also be observed in the PCS im-
ages (Additional file 2: Figure S2), which were possibly due
to the decomposition of ECCNSs into the secondary
nanoparticles when the pH decreased.
The porous properties of CaCO3 products have been
investigated by the N2 adsorption-desorption analyses
(Figure 3). The obtained CaCO3 product has a high BET
surface area of 82.14 m2/g, and the average pore size is
13.98 nm with narrow pore size distribution. Its BET
specific surface is higher than that of the reported
CaCO3 [39,42].
Figure 4 shows X-ray diffraction patterns of CCNSs pre-
pared in the system of the binary solvent and the standardCNSs. Inset: Corresponding Barret-Joyner-Halender (BJH) pore size
Figure 4 X-ray diffraction patterns of CCNSs and the standard
pattern of CaCO3 (JCPDS 47–1743).
Figure 5 Sedimentation photographs of CCNSs, ECCNSs, and
free etoposide in RPMI-1640 medium. After standing for 10 min
(a), 1 h (b), and 2 h (c).
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son with standard data of calcite, it was found that diffrac-
tion peaks of CCNSs were broadened due to the nanosize
effect, and no peaks of other phases was found, indicat-
ing the CCNSs are well crystallized and of high purity.
From the results of XRD, it can be seen that the sam-
ples retain the same crystal form of calcite.
CaCO3 shows two characteristic absorption peaks
centered at 875 cm−1 (bending vibration of calcite) and
745 cm−1 (bending vibration of vaterite) in its infrared
absorption spectrum [43]. In curve b of Additional file 3:
Figure S3, CCNSs display three strong absorption bands at
875, 1426, and 712 cm−1, which are characteristic absorp-
tion bands of calcite. It indicated that CCNSs are the crys-
tal form of calcite, which agrees with the results from XRD
patterns. The spectra of etoposide (c) shows the following
bands: 2,923 cm−1 (C-H stretch), 1,770 cm−1 (C=O stretch
of ester bond), 1,613 cm−1 (C=O stretch of carboxyl
methyl), and 1,056 cm−1 (C-O-C stretch), as well as the
bands at 1,487 cm−1 and 1,405 cm−1, corresponding to the
C=C stretching in the backbone of the aromatic
phenylring. Compared with that of CCNSs (b) and
etoposide (c), the spectra of ECCNSs (a) not only display
the visibly characteristic bands of CaCO3 (with a small
shift) but also show almost all etoposide characteristic
vibration, which indicates that that etoposide was suc-
cessfully packed into CCNSs.
Figure 5 presents the photographs of CCNSs, ECCNSs,
and free etoposide in RPMI-1640 medium supplemented
with 10% fetal bovine serum and 1% penicillin-
streptomycin solution, which were recorded at 10 min, 1
h, and 2 h after standing. It can be seen that both CCNSs
and ECCNSs disperse stably in RPMI-1640 medium, and
little sedimentation of the particles was observed after
standing for 2 h. In contrast with CCNSs and ECCNSs,
the free etoposide added in RPMI-1640 medium beganto precipitate and aggregate in the initial 10 min, and
most part of the sample still precipitated at the bottom
of the tube after standing for 2 h. Therefore, the embed-
ding of etoposide into CCNSs obviously enhanced the
dispersion and stability of the drug in medium solution.
The release of etoposide from ECCNSs in vitro is shown
in Figure 6. The drug release behaviors of ECCNSs were
studied at pH 7.4, 5.8, and 3, which modeled the different
environments of blood and normal tissue (pH 7.4), tumor
microenvironment (pH 5.8), and gastric juice (pH 3.0), re-
spectively. The etoposide released from the highly ordered
hierarchical calcium carbonate nanospheres gradually in-
crease as the pH value decrease. There is an initial burst
which could be attributed to the physical adsorption of a
small amount of etoposide. Then, a sustained release from
ECCNSs could be observed, and the cumulative drug re-
lease is about 80% at pH 3 after 120 h. At pH 7.4, the re-
lease amount was quite low and only approximately 30%
was released in 120 h, which suggested that the delivery
Figure 6 Release profiles of etoposide from ECCNSs under
simulated physiological conditions (pH 3.0, 5.8, and 7.4 at 37°C).
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outer drugs rather than the degradation of ECCNSs. At pH
5.8, about 50% of the loaded drug was released within 48 h,
which was much lower than the drug release at pH 3.
These results can demonstrate that the release of etoposide
from ECCNSs is a pH-sensitive controlled release system,
which is of particular feasibility in achieving the tumor-
targeted therapy. Suppose that oral administration is
chosen, the ECCNSs can ensure a stable delivery of
etoposide during blood circulation. When the nanohybridsFigure 7 The viability of HEK 293 T and SGC-7901 cells influenced by CC
results for HEK 293 T cell line with CCNSs, free etoposide, and ECCNSs after 24 a
10, 20, and 40 μg/mL. (c) and (d) growth inhibition assay results for SGC-7901 c
incubation. Diagrams were plotted as etoposide concentrations of 5, 10, 20, andaccumulate at the tumor site through the EPR effect, a fast
and stable etoposide release can be triggered in response to
extracellular or intracellular stimulus of tumor cells, where
pH value is lower than that in the normal tissue.
Figure 7a, b shows the viability of normal cells (HEK 293 T)
treated with CCNSs, free etoposide, and ECCNSs at various
concentrations (5, 10, 20, 40 μg/mL), for 24 and 48 h.
HEK 293 T cells treated with CCNSs all show over
80% survival rate, which indicates that the CCNSs show
low cytotoxicity and have good biocompatibility. Com-
pared with free etoposide, ECCNSs showed obviously
lower cytotoxicity against normal cells. It can be inferred
that embedding of etoposide into CCNSs can alleviate the
cytotoxicity of etoposide to normal cells.
Figure 7c, d shows the effect of etoposide formulation on
the inhibition against SGC-7901 cell growth. The results
showed the suppression of SGC-7901 cell growth by diffe-
rent nanohybrids was concentration and time dependent.
The inhibition rates of ECCNSs and the free etoposide are
72.66% and 41.40% over 48 h, respectively. Obviously,
ECCNSs showed higher suppression efficiency than free
etoposide against the growth of SGC-7901 cells. Synergistic
therapeutic effects occurred when etoposide was entrapped
by CCNSs. It is possible that good dispersivity and stability
of ECCNSs in culture medium (Figure 5) may lead to a
greater cellular uptake than that of free etoposide.
Then, the pH values of culture media for SGC-7901
cells were measured as 8.1 (0 h), 7.82 (24 h), and 6.76NSs, free etoposide, and ECCNSs. (a) and (b) growth inhibition assay
nd 48 h incubation. Diagrams were plotted as particle concentrations of 5,
ell line with CCNSs, free etoposide, and ECCNSs after 24 and 48 h
40 μg/mL. All experiments were carried out in triplicate.
Figure 8 FACS analysis of SGC-7901 cells stained with Annexin V-FITC and PI. (a) Cells did not treat with any agents as blank control, (b)
cells apoptosis induced by VP-16, (c) cells treated with the ECCNSs. In all panels, LR represents early apoptosis and UR represents late apoptosis.
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etoposide from ECCNSs may increase as the pH value of
the culture decreases because of its pH-sensitive con-
trolled release behavior investigated above. The stronger
cell inhibition of ECCNSs further confirms that the cell
uptake of nanoparticles, the decomposition of ECCNSs
as the pH descends, and the passive diffusion of the free
etoposide released from the ECCNSs, together helped to
achieve the cell inhibition effect.
The mechanism of cell growth inhibition by ECCNS
nanoparticles was studied using Annexin V-FITC Apop-
tosis Detection Kit. As we know, early apoptosis was char-
acterized by plasma membrane reorganization and was
detected by positive staining for Annexin V-FITC while
later stage apoptosis was characterized by DNA damage
and detected by positive staining for both Annexin V and
PI. In this study, we stained SGC-7091 cells with AnnexinFigure 9 Confocal laser scanning microscopy images of the etoposide
the predetermined point of 1, 2, and 4 h. In each case, 1, 2, and 3 indicateV-FITC and PI after the treatment of free etoposide or
ECCNSs (30 μg/mL) nanoparticles for 24 h. Meanwhile,
cells without any addition were set as control. As given in
Figure 8a, SGC-7901 cells without any additive showed
0.11% early apoptosis and 0.33% later apoptosis. The treat-
ment with etoposide led to 13.41% early apoptosis and
7.80% later apoptosis (Figure 8b). The results clearly reveal
that the early apoptosis increased to 42.72% and later apop-
tosis increased to 9.90% (Figure 8c) when the cells were
treated with ECCNSs. It is now well established that
etoposide-induced cleavage of DNA by topoisomerase II
can mediate the formation of chromosomal translocation
breakpoints, leading to the expression of oncogenic factors
responsible [44]. Etoposide can cause apoptosis cascade in
gastric cancer cells by coupling DNA damage to p53 phos-
phorylation through the action of DNA-dependent protein
kinase [45]. The percentage of both early apoptosis and. (Rows a, b, and c) and ECCNSs (rows d, e, f) on SGC-7901 cells. At
DAPI, FITC, and Merge, respectively. The scale bar represents 25 μm.
Figure 10 SGC-7901 cells were treated with 30 μg/mL etoposide in two forms of ECCNSs (f, g, and h) and void etoposide (b, c, and d).
As the plots show, the number of events (y-axis) with high fluorescence intensity (x-axis) increases by 4-h incubation with ECCNSs but without
any evident change for void etoposide. Negative control (a and e) includes nontreated cells to set their auto-fluorescence as ‘0’ value.
Peng et al. Nanoscale Research Letters 2013, 8:321 Page 9 of 11
http://www.nanoscalereslett.com/content/8/1/321later apoptosis in the ECCNSs-treated group remarkably
increased compared with free etoposide alone and un-
treated control, which indicated that ECCNSs were able to
accelerate the apoptosis processes of tumor cells. The result
also revealed that etoposide entrapped in CCNSs could en-
hance the efficient antitumor effect.
The CLSM image of the etoposide/ECCNSs is shown in
Figure 9. The high therapeutic effect by ECCNSs was in-
vestigated by the uptake behavior in SGC-7901 cells.
Thus, the effective therapy may result from the enhanced
intracellular delivery, the pH-sensitive release, and protec-
tion of etoposide by ECCNSs. Etoposide (rows a, b, c) and
ECCNSs (rows d, e, f ) passed through the cell membrane
of SGC-7901 cells and assembled in nucleus at the
predetermined point of 1, 2, and 4 h. These results dem-
onstrated that cellular uptake of SGC-7901 cell was time-
dependent, and the efficient cellular uptake of ECCNSsFigure 11 A representative illustration of ECCNSs targeting.was higher than that of the free etoposide. From the
CLSM image, it could also be seen that the CCNS carriers
could aggregate around the nucleus (blue fluorescence)
and even directly intrude into the nucleus.
Kinetic assessment of ECCNSs (Figure 10b, c, d) uptake
and void etoposide (Figure 10f, g, h) in SGC-7901 cell was
conducted by plotting the fluorescence peak of each sample
against the different incubation times of 1 h (b, f), 2 h (c, g),
and 4 h (d, h). The number of events with high intensity for
30 μg/mL etoposide increased when the incubation time
continued to 4 h, pretending its uptake into cells. At the
same time, etoposide did not show any significant change
in fluorescence intensity compared with ECCNSs. As
shown in Figure 10, the cellular fluorescence is much
higher when the etoposide was loaded on CCNSs, which
indicates that CCNSs, as a drug carrier, enhances the cell
uptake of etoposide. The fluorescence intensity of the
Peng et al. Nanoscale Research Letters 2013, 8:321 Page 10 of 11
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from CLSM images.
Controlled delivery of drug using carrier materials is
based on two strategies: active and passive targeting. The
former is technical sophisticated and suffering from many
difficulties. Otherwise, the latter is easier to implement
practically [46]. Many formulations have been used in the
representative passive-targeting strategies based on the EPR
effect [47]. Tumor vessels are often dilated and fenestrated
due to rapid formation of vessels that can serve the fast-
growing tumor while normal tissues contain capillaries with
tight junctions that are less permeable to nanosized particle
[11,48]. The EPR effect is that macromolecules can accu-
mulate in the tumor at concentrations five to ten times
higher than in normal tissue within 1 to 2 days [49]. Be-
sides, biomaterials with diameters more than 100 nm tend
to migrate toward the cancer vessel walls [50]. Therefore,
the EPR effect enables ECCNSs (secondary nanoparticles)
to permeate the tumor vasculature through the leaky endo-
thelial tissue and then accumulate in solid tumors. On one
hand, the uptake of ECCNSs by tumor cells can lead to the
direct release of etoposide into intracellular environment to
kill tumor cells. On the other hand, the pH-sensitive drug
release behavior for ECCNSs may lead to the low release of
etoposide from ECCNSs in pH neutral blood, and the rapid
release of the drug in relatively acidic extracellular fluids in
the tumor. In this way, the targeted delivery of etoposide to
tumor tissues may be possible by ECCNSs.
Referring to some previous reports [51,52], the pos-
sible mechanism for the targeted delivery of the ECCNSs
is illustrated in Figure 11. Most of the biodegradable
ECCNSs decompose into the secondary nanoparticles in
the vicinity of the tumor endothelium, with the release
of epotoside. The small therapeutic nanoparticles and
drugs readily pass through the endothelia into tumor tis-
sues for efficient permeability [53]. The degradation of
the materials in the endosomes or lysosomes of tumor
cells may determine the almost exclusive internalization
along clathrin-coated pits pathway. The multistage de-
composition of ECCNSs in blood vessels or tumor tissue
is likely to play a key role in determining their targeting
and biological activity [54].
Conclusions
In summary, we have proposed a facile method to pre-
pare mesoporous CCNSs formed by the multistage self-
assembled strategy in a binary solvent reaction system.
Further studies on CCNSs as carriers for etoposide
(loading capacity 39.7%) demonstrated their pH-sensitive
drug release profile and enhanced cytotoxicity by in-
creasing cellular uptake and apoptosis to tumor cell. The
cytotoxicity test and apoptosis test showed that the car-
rier of CCNSs was almost nontoxic and ECCNSs were
evidently more efficient than free etoposide in antitumoreffect and deliver activity. These results also indicated
that the hierarchical mesoporous CaCO3 nanospheres
(CCNSs) hold great promise to overcome the drawbacks
of water-insoluble drugs such as etoposide and thereby
enhance their therapeutic effect.
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